Jax DiEugenio

Jax DiEugenio joined MJH Life Sciences in 2024, first as an editorial intern before transitioning into a full-time assistant editor for OncLive. A recent College of New Jersey graduate, Jax majored in Journalism/ Professional Writing with minors in Public Health and Anthropology. He is also pursuing a Master's Degree in Public Health, concentrating on health communications.

Articles

Intersectionality, Leadership, and Empowerment Drive Jagsi as a Woman in Oncology

March 20th 2025

Reshma Jagsi, MD, DPhil, highlights her journey to becoming a radiation oncologist and the nuances of intersectionality as a woman in oncology.

Brentuximab Vedotin Combo Adds Another Targeted Option Beyond CD19/CD20 in R/R LBCL

March 19th 2025

Grzegorz S. Nowakowski, MD, discusses the FDA approval of brentuximab vedotin plus lenalidomide and rituximab for relapsed/refractory LBCL.

Dr Coombs on the Need for Consensus to Define High-Risk CLL

March 19th 2025

Catherine C. Coombs, MD, discusses the need to establish a standardized definition of high-risk CLL.

Ocular AEs From Mirvetuximab Soravtansine Do Not Impact HRQOL in FRα+ Platinum-Resistant Ovarian Cancer

March 18th 2025

Ocular adverse effects stemming from mirvetuximab soravtansine did not significantly affect HRQOL in FRα-positive platinum-resistant ovarian cancer.

Dr Fakih on the Future of Botensilimab and Balstilimab–Based Therapies in MSS mCRC

March 18th 2025

Marwan Fakih, MD, discusses the advancement of botensilimab/balstilimab–based combination therapies in microsatellite-stable colorectal cancer.

Penpulimab Gains NMPA Approval for First-Line Treatment of Recurrent or Metastatic NPC

March 18th 2025

Penpulimab received NMPA approval for first-line use with chemotherapy in recurrent or metastatic nasopharyngeal carcinoma.

FDA Grants Orphan Drug Designation to Bexobrutideg in Waldenström Macroglobulinemia

March 18th 2025

Bexobrutideg received orphan drug designation from the FDA for the treatment of patients with Waldenström macroglobulinemia.

Dr Sheen on Racial Disparities in Physiology, Genetic Testing in Breast Cancer

March 17th 2025

Melanie A. Sheen, MD, discusses a study aimed at determining differences in breast composition and assess racial disparities in access to and utilization of genetic counseling.

Dr Herrmann on Assessing Time Toxicity in Lung Cancer Trials

March 17th 2025

Amanda Herrmann, MD, discusses findings from the TIME-TOX Lung study, which retrospectively assessed the time toxicity associated with lung cancer clinical trials.

Avutometinib/Defactinib Combo Drives Responses in Recurrent Low-Grade Serous Ovarian Cancer

March 17th 2025

The combination of avutometinib and defactinib produced durable responses in recurrent low-grade serous ovarian cancer.

Venetoclax Plus Pegcrisantaspase Induces Remissions in R/R AML: With Ashkan Emadi, MD, PhD

March 17th 2025

Ashkan Emadi, MD, PhD, discusses how the combination of venetoclax plus pegcrisantaspase induced complete remissions in heavily pretreated patients with relapsed/refractory acute myeloid leukemia.

Real-World Analysis Confirms Efficacy/Safety of Dostarlimab Plus Chemotherapy in Advanced Endometrial Cancer

March 17th 2025

Findings from a real-world study confirm the efficacy and safety of dostarlimab plus chemotherapy in advanced endometrial cancer.

Durvalumab Secures EU Approval for LS-SCLC After CRT

March 17th 2025

The European Commission approved durvalumab for limited-stage small cell lung cancer without disease progression following chemoradiation.

Frontline Maintenance With Niraparib Plus Bevacizumab Is Active in Advanced Ovarian Cancer

March 16th 2025

Frontline maintenance with niraparib and bevacizumab showed efficacy and safety profiles that are in line with similar regimens in advanced ovarian cancer.

Puxitatug Samrotecan Demonstrates Efficacy, Manageable Safety in Advanced/Metastatic Endometrial Cancer

March 16th 2025

Puxitatug samrotecan demonstrated preliminary efficacy and manageable safety in advanced or metastatic endometrial cancer.

Dr Richter on Goals for Expanding T-Cell–Redirecting Therapies in Myeloma

March 14th 2025

Joshua Richter, MD, discusses the evolution of multiple myeloma treatment in recognition of Myeloma Awareness Month 2025.

AVA6000 Generates Early Efficacy, Is Safe in Advanced Salivary Gland Cancers

March 14th 2025

AVA6000 showed early efficacy and safety signals in previously treated, locally advanced or metastatic salivary gland cancers.

Dr Nathanson on the Role of Reversion Mutations in PARP Inhibitor Resistance in Breast Cancer

March 13th 2025

Katherine L. Nathanson, MD, discusses the impact of reversion mutations on resistance to PARP inhibitors across various DNA damage repair genes.

Nadofaragene Firadenovec May Propel Advances in Intermediate-Risk NMIBC Management

March 13th 2025

Neal D. Shore, MD, FACS, discusses the evaluation of nadofaragene firadenovec in intermediate-risk NMIBC and its potential effect on treatment strategies.

Fixed-Duration Mosunetuzumab Demonstrates Preliminary Activity in BTK Inhibitor–Exposed R/R MCL

March 13th 2025

Single-agent mosunetuzumab generated response rates in patients with relapsed/refractory MCL who previously received a BTK inhibitor.